Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Medtronic
Federal Trade Commission
US Department of Justice
Merck
Moodys
UBS
Harvard Business School
Julphar

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,351,834

« Back to Dashboard

Summary for Patent: 7,351,834
Title:.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy (Hyogo, JP), Scott; William (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert (North Haven, CT)
Assignee: Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:09/889,227
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,351,834

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,351,834

PCT Information
PCT FiledJanuary 12, 2000PCT Application Number:PCT/US00/00648
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/42012

Non-Orange Book US Patents Family Members for Patent 7,351,834

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,330 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Subscribe
7,528,255 Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors ➤ Subscribe
7,897,623 .omega.-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors ➤ Subscribe
8,124,630 .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Subscribe
7,928,239 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,351,834

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 73731 ➤ Subscribe
Taiwan I269791 ➤ Subscribe
Turkey 200102020 ➤ Subscribe
Tunisia SN00010 ➤ Subscribe
El Salvador 2001000004 ➤ Subscribe
Slovakia 287419 ➤ Subscribe
Slovakia 285532 ➤ Subscribe
Slovakia 9882001 ➤ Subscribe
Slovenia 1690853 ➤ Subscribe
Slovenia 1140840 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Colorcon
Dow
McKesson
Federal Trade Commission
Queensland Health
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot